A detailed history of Vanguard Group Inc transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,370,885 shares of RCKT stock, worth $116 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,370,885
Previous 5,447,565 1.41%
Holding current value
$116 Million
Previous $163 Million 11.38%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$26.16 - $30.74 $2.01 Million - $2.36 Million
-76,680 Reduced 1.41%
5,370,885 $145 Million
Q4 2023

Feb 14, 2024

BUY
$16.78 - $31.94 $14.2 Million - $26.9 Million
843,552 Added 18.32%
5,447,565 $163 Million
Q3 2023

Nov 14, 2023

BUY
$15.07 - $24.05 $61,560 - $98,244
4,085 Added 0.09%
4,604,013 $94.3 Million
Q2 2023

Aug 14, 2023

BUY
$16.59 - $23.6 $1.12 Million - $1.59 Million
67,504 Added 1.49%
4,599,928 $91.4 Million
Q1 2023

May 15, 2023

BUY
$15.79 - $22.6 $5.46 Million - $7.82 Million
345,882 Added 8.26%
4,532,424 $77.6 Million
Q4 2022

Feb 10, 2023

BUY
$15.5 - $22.76 $11.9 Million - $17.5 Million
769,031 Added 22.5%
4,186,542 $81.9 Million
Q3 2022

Nov 14, 2022

BUY
$12.37 - $18.41 $767,187 - $1.14 Million
62,020 Added 1.85%
3,417,511 $54.5 Million
Q2 2022

Aug 12, 2022

BUY
$7.96 - $16.64 $50,394 - $105,347
6,331 Added 0.19%
3,355,491 $46.2 Million
Q1 2022

May 13, 2022

BUY
$13.16 - $23.68 $631,969 - $1.14 Million
48,022 Added 1.45%
3,349,160 $53.1 Million
Q4 2021

Feb 14, 2022

BUY
$21.52 - $36.02 $1.2 Million - $2.01 Million
55,750 Added 1.72%
3,301,138 $72.1 Million
Q3 2021

Nov 12, 2021

BUY
$27.42 - $48.97 $1.03 Million - $1.84 Million
37,623 Added 1.17%
3,245,388 $97 Million
Q2 2021

Aug 13, 2021

BUY
$39.41 - $47.25 $126 Million - $152 Million
3,207,765 New
3,207,765 $142 Million

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $1.63B
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.